Status:
RECRUITING
A Prospective, Randomized, Subject and Vision-assessor Masked, Multicenter Study Comparing Bilateral Clareon PanOptix, Bilateral Clareon PanOptix Pro, and Mixed Clareon PanOptix Pro/Vivity Intraocular Lens Implantation in Cataract Subjects
Lead Sponsor:
Berkeley Eye Center
Collaborating Sponsors:
Sengi
Conditions:
Cataract
Eligibility:
All Genders
40+ years
Phase:
PHASE4
Brief Summary
Prospective, randomized, multicenter, multi-arm, subject and vision-assessor-masked, two stage study with Stage 1 as a three-arm initial enrollment period, followed by Stage 2 as a head-to-head study ...
Eligibility Criteria
Inclusion
- Adult cataract patients aged 40 years and older scheduled for age related cataract surgery in both eyes.
- Ability to understand and sign an ethics committee-approved informed consent form.
- Willingness and ability to attend all scheduled study visits as required by the protocol.
- Postoperative potential visual acuity of 20/25 or better in each eye, as determined by the investigator.
- Preoperative corneal astigmatism that can be corrected with a T3 or T4 toric IOL, or with a spherical IOL and LRIs or AKs resulting in a predicted postoperative astigmatism of less than 0.5 diopters (D).
- Ability to understand and complete questionnaires.
Exclusion
- Women who are pregnant, planning to become pregnant during the study, or breastfeeding.
- Ocular conditions that could confound study results, including moderate to severe corneal pathology, irregular astigmatism, moderate to severe dry eye, preexisting retinal diseases such as macular degeneration or diabetic retinopathy.
- Any form of confirmed glaucomatous damage (ie, mild, moderate, or severe glaucoma).
- Participation in another clinical study that could interfere with the results.
- Systemic conditions that may affect healing or visual outcomes (e.g., uncontrolled diabetes mellitus, certain autoimmune disorders).
- Subjects with nystagmus, strabismus, zonular laxity or dehiscence, and pseudoexfoliation.
- Prior ocular surgery (except for uncomplicated cataract surgery in the fellow eye).
- Participants desiring monovision.
- Any active ocular infection or inflammation (except for routine post-operative inflammation in the fellow eye)
- Psychiatric or cognitive disorders that may impair the ability to comply with study procedures or provide accurate self-assessments.
- RMS total higher-order aberrations (HOAs) \>0.70 µm or coma \>0.40 µm as measured by tomography or topography with a 4 mm pupil setting.
Key Trial Info
Start Date :
March 17 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2026
Estimated Enrollment :
320 Patients enrolled
Trial Details
Trial ID
NCT06922084
Start Date
March 17 2025
End Date
April 1 2026
Last Update
April 10 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Shafer Vision Institute
Plymouth Meeting, Pennsylvania, United States, 19462
2
Berkeley Eye Center
Houston, Texas, United States, 77027